GLUE (Monte Rosa Therapeutics) Institutional Ownership: 106.76% (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GLUE Monte Rosa Therapeutics Inc GLUE
34 GF Score
Price $21.97
! 5 Warning Signs
View Full Analysis

What is Monte Rosa Therapeutics Institutional Ownership?

Monte Rosa Therapeutics GLUE -4.52% 34 Institutional Ownership is 106.76% as of Jul. 14, 2026. GuruFocus rates GLUE with a GF Score™ of 34/100. The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Monte Rosa Therapeutics's institutional ownership is 106.76%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Monte Rosa Therapeutics's Insider Ownership is 1.09%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Monte Rosa Therapeutics's Float Percentage Of Total Shares Outstanding is 98.45%.

Monte Rosa Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Monte Rosa Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monte Rosa Therapeutics Institutional Ownership Chart

Monte Rosa Therapeutics Historical Data

The historical data trend for Monte Rosa Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 37.01 34.34 34.45 36.91 36.24 37.79 38.61 38.75 38.30 38.93
GLUE
34GF Score
Monte Rosa Therapeutics Inc GLUE
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monte Rosa Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 106.76% mean?
Monte Rosa Therapeutics (GLUE) has a Institutional Ownership of 106.76% as of Jul. 14, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Monte Rosa Therapeutics and its competitors.
Is Monte Rosa Therapeutics' Institutional Ownership too high?
Monte Rosa Therapeutics' current Institutional Ownership is 106.76%. Overall, Monte Rosa Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Monte Rosa Therapeutics' Institutional Ownership compare to SNDX and IOVA?
Monte Rosa Therapeutics' Institutional Ownership of 106.76% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Monte Rosa Therapeutics and its competitors. Monte Rosa Therapeutics's current Institutional Ownership is 106.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monte Rosa Therapeutics stock overvalued right now?
Monte Rosa Therapeutics (GLUE) has a current Institutional Ownership of 106.76%. The current Institutional Ownership is 106.76%. Monte Rosa Therapeutics' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Monte Rosa Therapeutics (GLUE), the current Institutional Ownership is 106.76% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monte Rosa Therapeutics Business Description

Address 321 Harrison Avenue, Suite 900, Boston, MA, USA, 02118
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
34GF Score

Get the complete analysis for GLUE

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.97
Price